Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
This clinical trial, called the COMBO-Seq study, is looking at the best order to give drug treatments for advanced kidney cancer (metastatic renal cell carcinoma). Today, doctors have two powerful types of medicine: immunotherapy, which trains the body's immune system to attack cancer cells, and targeted therapies, which are tablets that block cancer growth. While doctors know both types of medicine work well, they do not yet know which sequence gives patients the best long-term outcome. In this study, patients will be randomly split into two groups. One group starts with two immunotherapies combined, while the other starts with an immunotherapy combined with a targeted drug. If the cancer grows later on, patients switch to a targeted medicine. Researchers want to see which treatment order keeps the cancer controlled for longer, helps people live longer, and provides the best overall quality of life.
At a glance
What is this study about?
Kidney cancer is sometimes diagnosed after it has spread to other parts of the body, which doctors call metastatic renal cell carcinoma. Although advanced kidney cancer cannot usually be cured, treatments have improved greatly in recent years. Doctors commonly use two main approaches: immunotherapy, which helps your own immune system recognize and fight cancer cells, and targeted therapies (often called TKIs), which are daily tablets designed to block signals that cancer cells need to survive and multiply.
Both of these approaches are effective, and doctors often combine them. However, specialists still face an important question: what is the best order to give them? For example, is it better to start with two immunotherapy medicines together, and save targeted tablets for later if needed? Or is it better to start with an immunotherapy paired with a targeted tablet from day one?
The COMBO-Seq trial is a large phase 3 study designed to answer this question. By comparing these two treatment pathways side by side, researchers aim to find out which sequence controls the cancer for longer and gives patients the longest survival.
Finding the clearest answer will help the NHS and doctors worldwide choose the best, most effective treatment plan for people facing advanced kidney cancer in the future, while keeping unwanted side effects as low as possible.
Key takeaways
- Compares two different sequences of modern drug treatments for advanced kidney cancer.
- Uses proven immunotherapy drips and targeted daily tablets.
- Aims to discover which treatment order keeps cancer stable longer and improves survival.
- Requires regular clinic visits for drips, health checks, and routine scans.
- Participation is completely voluntary and will not impact your right to standard NHS care.
Who may be eligible?
This study is open to adults aged 18 and over who have been diagnosed with kidney cancer that has spread to other parts of the body (metastatic renal cell carcinoma). Both men and women can take part.
Because this trial looks at the very first steps of treatment, participants are usually people who are ready to begin their first major drug therapy for advanced kidney cancer. You should also be well enough to carry out daily tasks, attend regular hospital appointments, and swallow tablets.
Your hospital doctor will review other health details, such as your blood test results, heart, liver, and kidney health, to confirm whether taking part is safe for you. If you have had certain previous cancer treatments or have other major medical conditions, this trial might not be suitable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am at least 18 years old.
- I have been diagnosed with kidney cancer that has spread (metastatic renal cell carcinoma).
- I am preparing to start my first drug treatment for advanced kidney cancer.
- I am well enough to attend regular hospital appointments and scans.
- I am able to swallow tablets each day.
What does participation involve?
If you decide to take part, a computer will randomly place you into one of two treatment groups. Depending on your group, you will start with either two immunotherapy medicines given through a drip into a vein at the hospital, or an immunotherapy drip combined with daily targeted tablets to swallow at home. You will have regular hospital visits for treatment, blood tests, and scans (such as CT scans) to see how the cancer is responding. You will also be asked to complete short questionnaires about how you feel and your quality of life. If your cancer begins to grow at any point, your doctor will switch your care to the second step of the study plan, which involves taking a targeted tablet. You will stay on the study for as long as the treatment helps you and any side effects are manageable, which may be several months or years.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is the main goal of this trial?
The goal is to find out which sequence of immunotherapy and targeted drug treatments helps people with advanced kidney cancer live longer, healthier lives.
Can I choose which treatment group I join?
No. A computer assigns you to a group by chance. This makes the comparison fair and ensures the results are medically reliable.
How are the medicines given?
Immunotherapy is given as an intravenous drip in the hospital clinic, usually every few weeks. Targeted therapies are tablets that you swallow at home each day.
What happens if my cancer gets worse during the trial?
The trial is specially designed for this. If the first combination stops working, your care team will switch you to a different targeted tablet treatment as part of the study plan.
Do I have to pay for any of the study treatments?
No. In the UK, all trial medications, extra scans, and study-related visits are provided free of charge through the hospital.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.